ZyVersa is a clinical stage specialty biopharmaceutical company with two licensed proprietary product platforms invented by top tier research scientists at University of Miami Miller School of Medicine. Our focus is on inflammatory and renal diseases which have a global total addressable market of around $150 billion and $15 billion, respectively.

For treatment of inflammatory diseases, ZyVersa is well positioned in the inflammasome space with a highly differentiated monoclonal antibody that inhibits inflammasome ASC (IC 100). Unlike NLRP3 inhibitors, which target only the NLRP3 inflammasome, by targeting ASC, IC 100 potentially inhibits twelve or more types of inflammasomes. This is expected to better control inflammation in numerous inflammatory diseases that are triggered by activation of more than one type of inflammasome. Likewise, by targeting ASC, IC 100 inhibits inflammasome formation and initiation of the inflammatory cascade. IC 100 also inhibits intra- and extracellular ASC specks to attenuate propagation and systemic spread of inflammation that leads to co-morbidities. The lead indication for IC 100 is obesity and its associated metabolic complications. IC 100 has strong indication expansion potential in a broad range of CNS and peripheral inflammatory diseases.